Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IONS vs ALNY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ALNY Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

ALNY Overall Winner 6-Pillar Tally: IONS 1 – 5 ALNY Matrix Metrics: IONS 3 – 7 ALNY

As of Nov 16, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas ALNY carries 60.1/100 (BUY) at $159.64 (15.2x Forward P/E, 19.5% operating margin).

  • Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. ALNY 60.1/100 BUY), ALNY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (19.5% vs. -58.8% operating margin) and revenue trajectory (+16.7% vs. +54.9% YoY).
  • Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile ALNY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IONS vs ALNY
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07
ALNY NASDAQ Head-to-Head Winner
Alnylam Pharmaceuticals, Inc.
Pharmaceutical Preparations
$159.64
-3.27% 1D
Market Cap $21.0B
TTM Revenue $5.01B
Forward P/E 15.2x
Beta / 30D Vol 0.54β · 96% Vol
Unified Composite Score
60.1 / 100 BUY
Tech 91.0 Fund 77.0 Flow 67.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.0%), weak momentum, RSI 33
RSI-14: 32.6 · SMA20: $183.70 · SMA50: $217.12

6-Pillar Scorecard Institutional Category Breakdown (IONS 1 – 5 ALNY)

Columns: Metric · IONS · ALNY
1. Valuation Multiples ALNY
Forward P/E 90.9x 15.2x
Trailing P/E 90.9x 7.9x
PEG Ratio N/M 0.22x
EV / Revenue 6.2x 4.1x
2. Growth & Scale ALNY
Revenue Growth (YoY) +54.9% +16.7%
Earnings Growth (YoY) -43.7% +633.5%
TTM Revenue (USD) $960M $5.01B
Market Cap $4.7B $21.0B
3. Profitability & Quality ALNY
Gross Margin 3.0% 77.3%
Operating Margin -58.8% 19.5%
Net Profit Margin -56.9% 52.8%
Return on Equity (ROE) -108.0% 138.1%
4. Balance Sheet & Cash Flow ALNY
Cash Generation (TTM) -$623M $752M
Cash Flow Margin -64.9% 15.0%
Net Cash / Leverage $1.33B Net Debt (4.14x D/E) $492M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ALNY
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 59.9% (17th %ile) 48.5% (29th %ile)
Put/Call OI Skew 1.81x (Put-Skewed) 0.37x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat IONS
OpEx & R&D Intensity 61.8% of Rev ($593M) 57.8% of Rev ($2.90B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IONS (3) vs ALNY (7)
Institutional Metric IONS ALNY Criterion Row Edge
Market Capitalization
Scale
$4.7B $21.0B Larger Scale ALNY
Trailing P/E Ratio
Valuation
90.9x 7.9x Lower Multiple ALNY
Forward P/E Ratio
Valuation
90.9x 15.2x Lower Multiple ALNY
Revenue Growth (YoY)
Growth
+54.9% +16.7% Higher Growth IONS
Operating Margin (TTM)
Profitability
-58.8% 19.5% Higher Margin ALNY
Net Profit Margin
Profitability
-56.9% 52.8% Higher Margin ALNY
Return on Equity (ROE)
Capital Efficiency
-108.0% 138.1% Higher ROE ALNY
52-Week Range Position
Momentum
2% ($27–$87) 3% ($149–$477) Stronger Trend ALNY
Beta / 30D Volatility
Risk Regime
0.18β · 86% Vol 0.54β · 96% Vol Lower Realized Risk IONS
Unified Institutional Score
Composite Signal
63.9 / 100 (BUY) 60.1 / 100 (BUY) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$960M $5.01B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.0% 77.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.2x EV/Rev 0.22x PEG · 4.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$623M ($1.33B Net Debt (4.14x D/E)) $752M ($492M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ALNY +2.34 pp
IONS: -33.48% · ALNY: -31.14%
3M Horizon ALNY +21.92 pp
IONS: -52.09% · ALNY: -30.17%
6M Horizon ALNY +16.38 pp
IONS: -60.61% · ALNY: -44.23%
1Y Horizon IONS +5.73 pp
IONS: -59.1% · ALNY: -64.83%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IONS Revenue ALNY Revenue IONS Op. Margin ALNY Op. Margin Margin Leader
FY2018 $600M $70M -10.2% -1087.6% IONS
FY2019 $1.12B $220M 32.6% -427.5% IONS
FY2020 $730M $490M -23.6% -168.1% IONS
FY2021 $810M $840M -3.7% -83.9% IONS
FY2022 $590M $1.04B -69.8% -75.7% IONS
FY2023 $790M $1.83B -44.9% -15.4% ALNY
FY2024 $710M $2.25B -67.4% -7.9% ALNY
FY2025 $940M $3.71B -40.4% 13.5% ALNY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ALNY BREAKDOWN
52d in phase · OBV NEUTRAL
Current IV 48.5%
IV Percentile 29th %ile
Put/Call OI Skew 0.37x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ALNY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published
ALNY Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $21.0B market capitalization and 19.5% operating margin.
OpEx & R&D Reinvestment 57.8% of Rev ($2.90B)
90D Engineering Disclosures 0 Published

Investor FAQ IONS vs ALNY Key Questions & Quantitative Answers

As of Nov 16, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas ALNY carries 60.1/100 (BUY) at $159.64 (15.2x Forward P/E, 19.5% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. ALNY 60.1/100 BUY), ALNY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (19.5% vs. -58.8% operating margin) and revenue trajectory (+16.7% vs. +54.9% YoY). Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile ALNY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ALNY leads the Growth & Scale pillar: IONS posts +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin), compared with ALNY at +16.7% YoY revenue growth and +633.5% YoY earnings growth on $5.01B TTM revenue (77.3% gross margin, 19.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IONS cumulative revenue shifted +56.7% while ALNY shifted +5200.0%. In operating R&D and SG&A reinvestment, IONS deploys 61.8% of Rev ($593M) (0 90-day corporate R&D disclosures) versus 57.8% of Rev ($2.90B) (0 disclosures) for ALNY.

ALNY screens cheaper on headline valuation multiples. IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin), whereas ALNY trades at 15.2x Forward P/E, 7.9x Trailing P/E, 0.22x PEG, and 4.1x EV/Revenue (15.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONS (-108.0% ROE) versus ALNY (138.1% ROE) capital efficiency.

In options market volatility and institutional positioning, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk). By comparison, ALNY carries 48.5% implied volatility (29th %ile, Balanced (25th–60th %ile)), a 0.37x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.54β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.